New combo therapy aims to slow advanced breast cancer

NCT ID NCT04448886

Ongoing Disease control Sponsor: Ana C Garrido-Castro, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding pembrolizumab (Keytruda) to sacituzumab govitecan helps people with a common type of advanced breast cancer (HR+/HER2-). About 110 participants receive either the combination or sacituzumab alone. The goal is to see if the combo delays cancer growth longer. This is not a cure; treatment aims to control the disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast carcinoma breast neoplasm Her2-receptor negative breast cancer hormone receptor-positive breast cancer invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-NEGATIVE BREAST CANCER HR-POSITIVE BREAST CANCER INVASIVE BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

DF/BWCC in Clinical Affiliation with South Shore Hospital

South Weymouth, Massachusetts, 02190, United States
DFCI @ Foxborough

Foxborough, Massachusetts, 02035, United States
DFCI @ Milford Regional Hospital

Milford, Massachusetts, 01757, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University/Winship Cancer Institute

Atlanta, Georgia, 30322, United States
University of Chicago Medical Center

Chicago, Illinois, 60637, United States
University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, 27599, United States
University of Pennsylvania-Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.